Gary’s practice focuses on investigation and dispute resolution matters for multinational and Asia-based companies. Gary has extensive experience in investigating allegations of corruption, fraud, conflict of interest, and other business misconduct in various industries including IT, finance, medical products, real estate, and manufacturing. He frequently assists multinational investors in pre-investment anti-corruption due diligence reviews of investments in China and other jurisdictions, as well as regulatory risk assessments of China business operations.
Gary also advises multinational companies in negotiating and litigating China-related business disputes. His experience includes assisting clients in connection with disputes arising out of Sino-foreign joint ventures, private antitrust enforcement, intellectual property, complex commercial contracts, and other business matters. In addition, he has extensive experience in assisting multinational companies in coordinating responses to Chinese regulatory inquiries.
Gary is a Registered Foreign Lawyer with the Law Society of Hong Kong. He passed the PRC Bar Exam in 2005. Fluent in English, Mandarin, and Cantonese, he once worked as an in-house counsel for a major Fortune 500 company, advising on various contentious and regulatory matters in China.
- U.S. technology company in internal investigation of potential FCPA and corruption issues in China involving interactions with third party business consultants and Chinese government officials.
- U.S. technology company in internal investigation of alleged bribery and fraudulent practices of senior management in China relating to sale of IT products through government procurement bids.
- U.S. semiconductor company in internal investigation of potential FCPA and corruption issues in China, the U.S., and Europe involving cooperation with third party business consultants and interaction with Chinese state-owned enterprises.
- Former senior executive of a major international investment bank in U.S. government investigations into hiring practices in Asia.
- U.S. medical device company in M&A due diligence review of a China-based medical device company concerning anti-corruption internal controls and compliance with the FCPA and PRC anti-corruption laws.
- Major U.S. private equity firm in pre-transaction FCPA and anti-corruption due diligence related to investment in a commercial real estate business in China.
- Major international consulting company in M&A due diligence review of China-based companies concerning anti-corruption, internal controls, and compliance with PRC competition laws.
- Two major international chemical companies in China compliance matters concerning environmental protection, product import, work safety, and other regulatory areas.
- Hong Kong listed Chinese companies in response to enquiries from Hong Kong regulatory authorities concerning operational and financial issues in mainland China.
- U.S. software company in a private anti-monopoly litigation alleging abuse of market dominance brought by former business partner in a PRC court.
- Major Japanese chemical company in a Sino-foreign equity joint venture dispute with a Chinese SOE group concerning two joint venture companies in China.
- U.S. technology company in connection with PRC court proceedings against Chinese distributor arising out of distribution of electrical equipment.
- Leading Chinese financial database company in shareholder dispute and intellectual property-related dispute with U.S.-based minority shareholders.
- U.S. software company in a dispute with its China distributor and related internal investigation of alleged misconduct by the software company’s China managers.
- U.S. software company in a computer software copyright infringement action against a Chinese company in a PRC court.
- Major Chinese telecom company in a contractual dispute with business partners in the U.S. and China concerning complex telecom service contract performance issues.